Entries by admin@ask-gene.com

AskGene Achieves “First in Human” Milestone for ASKG915, A First-in-Class Anti-PD-1/IL-15 Prodrug for the Treatment of Solid Tumors

Camarillo, California, August 21, 2023 – AskGene Pharma Inc. is pleased to announce that the first patient has been dosed at Columbia University Irving Medical Center in New York City in the phase I clinical trial of ASKG915. The study is an open label, multi-regional phase I clinical trial evaluating the safety, tolerability, and pharmacokinetics […]

AskGene IGCC 2023 Oral Presentation: Latest Results of ASKB589 Phase I/II Trial

Camarillo, California, June 16, 2023 – AskGene Pharma Inc. today gave an oral presentation at the 15th International Gastric Cancer Congress (IGCC 2023) in Yokohama, Japan of the latest clinical results from NCT04632108 for ASKB589, an anti-CLDN18.2 antibody, for the treatment of solid tumors. Presentation Details NCT04632108 is a first-in-human study evaluating the safety, tolerability, […]

AskGene Will Give an Oral Presentation on the Latest Clinical Results for ASKB589 at IGGC 2023

Camarillo, California, June 2, 2023 – AskGene Pharma Inc. is pleased to announce its participation in the prestigious 15th International Gastric Cancer Congress (IGCC 2023), scheduled to take place on June 14-17, 2023 in Yokohama, Japan. At the conference, AskGene will give an oral presentation on the latest clinical results of NCT04632108 for ASKB589, an […]

AskGene Presents Encouraging Clinical Results on ASKB589 at ASCO-GI 2023

Camarillo, California, January 24, 2023 – AskGene Pharma Inc. presented encouraging clinical results for ASKB589, an anti-CLDN18.2 antibody, at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium (ASCO-GI 2023) in San Francisco on January 19-21, 2023. The results were from clinical trial NCT04632108, a Phase I/II, two-part, dose escalation and expansion study to evaluate […]

AskGene Announces Completion of First Human Dosing of ASKG315, The First IL-15 Prodrug in Clinical Development

Camarillo, California, December 30th, 2022 – AskGene Pharma Inc. is pleased to announce that the first patient completed their first dose (Cycle 1, Day 1) in the phase I clinical trial of ASKG315 in Shanghai, China.  The study is an open label, multicenter phase I clinical trial evaluating the safety, tolerability, and pharmacokinetics of ASKG315 […]

AskGene Announces Clearance of IND Application by US FDA for ASKG915, A First-in-Class Anti-PD-1-IL-15 Prodrug Fusion Molecule for the Treatment of Patients with Solid Tumors

Camarillo, California, December 30th, 2022 – AskGene Pharma Inc. is pleased to announce that the United States Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for the clinical development of ASKG915, a novel and proprietary anti-PD-1-IL-15 prodrug fusion molecule for the treatment of cancer.  Under this IND, AskGene will soon […]

AskGene Announces Submission of IND to FDA for ASKG915

Camarillo, California, November 21st, 2022 – AskGene Pharma Inc. is pleased to announce the submission of an Investigational New Drug (IND) application for ASKG915 to the United States Food and Drug Administration (FDA).  ASKG915 is a recombinant human anti-PD-1 monoclonal antibody and IL-15 prodrug fusion protein for oncology indications. Jian-Feng (Jeff) Lu, Ph.D., CEO of […]

AskGene Presents Latest Results on ASKG315 and ASKG915 at SITC 2022

Camarillo, California, November 15th, 2022 – AskGene presented the pre-clinical results of ASKG315 (IL-15 prodrug) and ASKG915 (PD-1/IL-15 prodrug) at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting in Boston on November 8 – 12, 2022.  For ASKG315 phase I clinical study design was also presented.  The two posters were: #1101, Chunxiao Yu et […]

AskGene Announces Appointment of Chief Medical Officer and VP of Preclinical & Clinical Pharmacology

Camarillo, California, August 19, 2022 – AskGene Pharma Inc. (AskGene) today announced the appointment of Barbara Hickingbottom, J.D., M.D. as Chief Medical Officer and Matt Hsu, Ph.D. as VP of Preclinical and Clinical Pharmacology.  Dr. Hickingbottom will be responsible for leading the global clinical development of AskGene, including pipeline strategy, clinical development plans and operations, […]

AskGene Pharma Announces First Development Milestone in License Agreement with AffaMed for the Development of ASKG712 in Retinal Disease

Camarillo, California, June 20, 2022 – AskGene Pharma Inc., an innovative clinical-stage biotech company, announces that its partner AffaMed has dosed the first patient in its US Phase 1 study of ASKG712 (AM712), a novel proprietary bispecific biologic molecule blocking both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) for the treatment of retinal diseases. The study […]